Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Firefly Neuroscience (AIFF) Change in Receivables (2016 - 2025)

Firefly Neuroscience has reported Change in Receivables over the past 15 years, most recently at $10000.0 for Q4 2025.

  • Quarterly results put Change in Receivables at $10000.0 for Q4 2025, up 109.8% from a year ago — trailing twelve months through Dec 2025 was $28000.0 (down 24.32% YoY), and the annual figure for FY2025 was $28000.0, down 24.32%.
  • Change in Receivables for Q4 2025 was $10000.0 at Firefly Neuroscience, up from -$13000.0 in the prior quarter.
  • Over the last five years, Change in Receivables for AIFF hit a ceiling of $1.9 million in Q2 2022 and a floor of -$2.1 million in Q3 2022.
  • Median Change in Receivables over the past 5 years was $7210.0 (2022), compared with a mean of -$15481.2.
  • Biggest five-year swings in Change in Receivables: crashed 665.7% in 2021 and later soared 5300.0% in 2025.
  • Firefly Neuroscience's Change in Receivables stood at -$1.2 million in 2021, then soared by 108.05% to $97385.0 in 2022, then tumbled by 56.87% to $42000.0 in 2023, then tumbled by 342.86% to -$102000.0 in 2024, then skyrocketed by 109.8% to $10000.0 in 2025.
  • The last three reported values for Change in Receivables were $10000.0 (Q4 2025), -$13000.0 (Q3 2025), and $52000.0 (Q2 2025) per Business Quant data.